No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block
Research output: Contribution to journal › Journal article › peer-review
The therapeutically available quinolone antibiotic moxifloxacin has been used as a positive control for prolonging the QT interval in both clinical and non-clinical studies designed to assess the potential of new drugs to delay cardiac repolarization. Despite moxifloxacin prolonging QT, it has not been shown to cause torsades de pointes arrhythmias (TdP). Azithromycin is a macrolide antibiotic that has rarely been associated, clinically, with cases of proarrhythmia. As there is a lack of clinical data available, the cardiac safety of these drugs was assessed in a TdP-susceptible animal model by evaluating their repolarization and proarrhythmia effects.
|Journal||British Journal of Pharmacology|
|Number of pages||10|
|Publication status||Published - Dec 2006|
- Anesthesia, Animals, Anti-Arrhythmia Agents, Anti-Bacterial Agents, Arrhythmias, Cardiac, Aza Compounds, Azithromycin, Dogs, Dose-Response Relationship, Drug, Electric Stimulation, Electroencephalography, Electrophysiology, Heart Block, Heart Rate, Long QT Syndrome, Phenethylamines, Quinolines, Sulfonamides, Torsades de Pointes